Cargando…
Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer
SIMPLE SUMMARY: How a cure for primary breast cancer after (neo)adjuvant therapy can be achieved at the molecular level remains unclear. Immune activation by anticancer drugs may contribute to the eradication of residual tumor cells by postoperative (neo)adjuvant chemotherapy. In addition, chemother...
Autores principales: | Kim, Ryungsa, Kin, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507525/ https://www.ncbi.nlm.nih.gov/pubmed/34638242 http://dx.doi.org/10.3390/cancers13194756 |
Ejemplares similares
-
Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease
por: Kim, Ryungsa, et al.
Publicado: (2021) -
Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer
por: Kim, Ryungsa, et al.
Publicado: (2021) -
Current Status and Prospects of Anesthesia and Breast Cancer: Does Anesthetic Technique Affect Recurrence and Survival Rates in Breast Cancer Surgery?
por: Kim, Ryungsa, et al.
Publicado: (2022) -
Breast cancer recurrence and survival rates in patients who underwent breast‐conserving surgery under non‐mechanically ventilated anesthesia
por: Kim, Ryungsa, et al.
Publicado: (2022) -
Outcomes in patients with non‐invasive breast carcinoma
por: Kim, Ryungsa, et al.
Publicado: (2022)